PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Shock teams and ECMO save lives in massive STEMI

2013-03-11
(Press-News.org) MINNEAPOLIS, MN - March 9, 2013 - The use of extracorporeal membrane oxygenation (ECMO), accompanied by mechanical CPR, in patients with massive myocardial infarctions can lead to unexpected survival. These study findings are being presented March 9 at the American College of Cardiology Scientific Sessions.

ECMO is an advanced technology that functions as a replacement for a critically ill patient's heart and lungs. This is the first report of combined ECMO, mechanical CPR and therapeutic hypothermia (TH) use within a STEMI Network.

"For many patients who present with a severe heart attack, or ST-elevation myocardial infarction (STEMI), complicated by cardiogenic shock that progresses to cardiac standstill, the result is almost uniformly fatal," says Michael R. Mooney, MD, a research cardiologist at the Minneapolis Heart Institute Foundation (MHIF) and a physician at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis. "This aggressive approach despite its complexity extends our ability to salvage the most devastating complication of acute MI."

The patients in this study were a consecutive series with STEMI meeting criteria for ECMO from August 2011 to October 2012. The Shock Team comprised of a perfusionist, an advanced heart failure cardiologist, an interventional cardiologist and a cardiac surgeon developed a protocol and a process for emergency ECMO (E-ECMO) in the CV lab. This same team was then used to implement E-ECMO.

The study included five patients (three males) with a median age of 64 years. The median time of cardiac arrest from the initiation of ECMO was 52 minutes, and ECMO was required for a median time of 4 days in these patients. After ECMO was initiated, therapeutic hypothermia was used in 4 of the cases. Mechanical CPR devices were used in all cases.

Of the five patients, four survived to hospital discharge and all of the survivors had "good neurologic recovery at discharge," Mooney reports. Of the four survivors, discharge ejection fraction improved from 0-10% to a median of 45%. Blood transfusions were required in all cases.

This group of patients account for nearly half of all deaths within a STEMI network and no effective treatment was previously available. "ECMO, along with mechanical CPR, and TH can provide survival in situations previously regarded as uniformly fatal. Therefore, ECMO may have a role in selected PCI centers with advanced specialized teams with the appropriate experience," stated Mooney.

### About the Minneapolis Heart Institute Foundation The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical research and innovative education programs. MHIF's mission is to promote and improve cardiovascular health, quality of life and longevity for all. Scientific Innovation and Research – Publishing more than 120 peer-reviewed studies each year, MHIF is a recognized research leader in the broadest range of cardiovascular medicine. Each year, cardiologists and hospitals around the world adopt MHIF protocols to save lives and improve patient care. Education and Outreach – Research shows that modifying specific health behaviors can significantly reduce the risk of developing heart disease. Through community programs, screenings and presentations, MHIF educates people of all walks of life about heart health. The goal of the Foundation's community outreach is to increase personal awareness of risk factors and provide the tools necessary to help people pursue heart- healthy lifestyles.

About the Minneapolis Heart Institute® The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.

Contact: Steve Goodyear
Minneapolis Heart Institute Foundation
612-863-1658


ELSE PRESS RELEASES FROM THIS DATE:

Niacin therapy shows no benefits, has some harmful effects

2013-03-11
SAN FRANCISCO (March 9, 2013) — A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) is the largest-ever study of niacin, commonly used to raise ...

Drug protects against kidney injury from imaging dye in ACS patients

2013-03-11
SAN FRANCISCO (March 10, 2013) —High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. This group of patients is at high risk for kidney damage related to contrast agents used in imaging tests. Previous studies have demonstrated the kidney-protective value of various statins administered before patients undergo ...

Encouraging early results for redesigned Sapien valve

2013-03-11
SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session. PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien ...

New biolimus stent equal to everolimus stent at 1 year

2013-03-11
SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. Drug-eluting stents are structures placed inside narrowed coronary arteries to restore proper blood flow. A polymer coating on these devices slowly releases a drug designed to prevent restenosis—another blockage at the same site—and prevent a second ...

Fewer adverse events with 'double kissing' crush stent than culotte

2013-03-11
SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. DKCRUSH-III is the first head-to-head comparison of double kissing (DK) crush and culotte stent techniques in coronary artery disease. The study focused on bifurcation lesions, which involve a main branch and a smaller side branch ...

Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial

2013-03-11
SAN FRANCISCO (March 10, 2013) — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session. Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events—blood-flow reductions ...

New anti-clotting drug more effective than current treatment

2013-03-11
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine. Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures. ...

Magnet ingestion by young children serious and growing problem

2013-03-11
Physicians and parents must be aware of the growing danger of magnet ingestion by children because magnets can adhere to each other and cause life-threatening problems such as bowel perforations, a new case study illustrates in CMAJ. "Modern magnet technology has transformed what was once an esoteric subtype of foreign-body ingestion into a common and lethal threat," writes Dr. Daniel Rosenfield, Department of Paediatrics, The Hospital for Sick Children (SickKids), with coauthors. In the past, magnet ingestion generally could be treated with a wait-and-see approach, ...

Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect

2013-03-11
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells – without affecting surrounding, healthy cells. The first study, published today in the journal Oncogene, worked with acute myeloid leukemia (AML), for which current chemotherapies offer a cure rate of only about 55 percent. "In about 2/3 of all AML patients and about 90 percent of adult AML patients, we found that the Mer receptor was upregulated. Mer receptor protein ...

EARTH: Well-healed faults produce high-frequency earthquake waves

2013-03-11
Alexandria, VA – Much like our voices create sound waves with a variety of low and high pitches, or frequencies, earthquakes produce seismic waves over a broad spectrum. The seismic waves' frequencies determine, in part, how far they travel and how damaging they are to human-made structures. However, the inaccessibility of fault zones means that very little is known about why and how earthquakes produce different frequencies. With the help of a new tabletop model, scientists have now identified how a process known as fault healing can shape seismic waves and potentially ...

LAST 30 PRESS RELEASES:

Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training

Day-long conference addresses difficult to diagnose lung disease

First-ever cardiogenic shock academy features simulation lab

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

[Press-News.org] Shock teams and ECMO save lives in massive STEMI